{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["63(5)"],"submitter":["Poola S"],"pubmed_abstract":["<h4>Background</h4>Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation.<h4>Aim</h4>The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.<h4>Methods</h4>We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolv"],"journal":["Alimentary pharmacology & therapeutics"],"pagination":["592-602"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12904191"],"repository":["biostudies-literature"],"pubmed_title":["Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment."],"pmcid":["PMC12904191"],"pubmed_authors":["Sewell K","Yang Z","Poola S","Kratzer M","Tillmann HL"],"additional_accession":[]},"is_claimable":false,"name":"Meta-Analysis: High anti-HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment.","description":"<h4>Background</h4>Hepatitis B virus (HBV) reactivation is a serious complication in patients receiving chronic immunosuppression. Anti-CD20 agents such as Rituximab are considered high risk for HBV reactivation (> 10%); therefore, antiviral prophylaxis is recommended for all anti-HBc positive patients. Some studies have suggested that patients with resolved HBV infection and higher hepatitis B surface antibody (anti-HBs) titer have a higher level of protection against reactivation.<h4>Aim</h4>The purpose of this study was to systematically review the role of anti-HBs titer on HBV reactivation in patients on rituximab while not on antiviral therapy/prophylaxis.<h4>Methods</h4>We systematically reviewed all studies that discussed HBV reactivation in patients on rituximab therapy with resolv","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-15T16:39:11.273Z","creation":"2026-07-07T03:08:26.98Z"},"accession":"S-EPMC12904191","cross_references":{"pubmed":["41390946"],"doi":["10.1111/apt.70490"]}}